In Israel, Novartis is focusing on marketing and clinical trials, but the country's president, Elad Maron, says: “We know we can do more. We want to leave our mark outside of Israel.”
“Novartis is one of the leaders in its field in Israel. It provides treatment to about 650,000 people in Israel at any given moment, and is conducting 70 clinical trials in different centers. Every month, the company provides compassionate care to 180,000 patients.” This was said by the President of Novartis Israel, Elad Maron, at the Novartis-Israel Health Innovation Meeting, which was held at the Startup Nation Central offices in Tel Aviv, in cooperation with the aMoon Fund.
Related articles
The CEO decides which drugs Novartis will develop
The scout who learned to look for the quiet
“We seek star researchers and pioneers in their fields.”
Startup Nation Central data reveals opportunities
In Israel, Novartis is focusing on commercialization and clinical trials, but Maron says: “We know we can do more. We want to leave a mark outside of Israel, among other things by being a bridge between Israel and the world.” The goal is to take Israeli innovation around the world by establishing collaborations with Novartis, and with both Israeli biomedical companies and academic institutions in Israel.
Maron was appointed president of Novartis Israel about two years ago. Until now, the company has not had much cooperation with the Israeli ecosystem, but Novartis seems determined to change that, and this decision is supported by a large delegation that came to the conference from abroad.
Novartis and Globes collaborated to cover the conference in accordance with editorial standards and considerations that are important to Globes readers. The conference was held in collaboration with health technology and life sciences investment fund aMoon and Startup Nation Central.
Dr. Roni Gal and Elad Maroun Credit: Kadia Levy
